Found 255 chains in Genus chains table. Displaying 1 - 50. Applied filters: Proteins

Search results query: Catalytic domain of cyclic nucleotide phosphodiesterase 4b2b

Total Genus Sequence Length pdb Title
127 324 3tgeA A novel series of potent and selective pde5 inhibitor1
127 324 3tggA A novel series of potent and selective pde5 inhibitor2
133 325 5k1iA Pde4 crystal structure in complex with small molecule inhibitor
115 312 5k9rA Pde10a with imidazopyrazine inhibitor
130 313 5i2rA Human pde10a in complex with 3-(2-phenylpyrazol-3-yl)-1-[3-(trifluoromethoxy)phenyl]pyridazin-4-one
126 307 5c29A Pde10 complexed with 6-chloro-2-cyclopropyl-5-methyl-n-propyl-pyrimidin-4-amine
127 323 5c2eA Pde10 complexed with6-chloro-n-[(2,4-dimethylthiazol-5-yl)methyl]-5-methyl-2-[2-(2-pyridyl)ethoxy]pyrimidin-4-amine
136 325 5c28A Pde10 complexed with 6-chloro-2-cyclopropyl-5-methyl-pyrimidin-4-amine
126 308 5c2hA Pde10 complexed with 6-chloro-n-[(2,4-dimethylthiazol-5-yl)methyl]-5-methyl-2-[3-(2-quinolyl)propoxy]pyrimidin-4-amine
133 323 5c2aA Pde10 complexed with 6-chloro-2-cyclopropyl-n-[(2,4-dimethylthiazol-5-yl)methyl]-5-methyl-pyrimidin-4-amine
135 325 5c1wA Pde10 complexed with 4,6-dichloro-2-cyclopropyl-5-methyl-pyrimidine
147 335 5b25A Crystal structure of human pde1b with inhibitor 3
125 315 5b4lA Crystal structure of the catalytic domain of human pde10a complexed with 1-(cyclopropylmethyl)-5-(2-(2,3-dihydro-1h-imidazo[1,2-a]benzimidazol-1-yl)ethoxy)-3-(1-phenyl-1h-pyrazol-5-yl)pyridazin-4(1h)-one
126 322 4ys7A Co-crystal structure of 2-[2-(5,8-dimethyl[1,2,4]triazolo[1,5-a]pyrazin-2-yl)ethyl]-3-methyl-3h-imidazo[4,5-f]quinoline (compound 39) with pde10a
128 321 4yqhA 2-[2-(4-phenyl-1h-imidazol-2-yl)ethyl]quinoxaline (sunovion compound 14) co-crystallized with pde10a
137 338 4htzA Crystal structure of pde2 catalytic domain in space group p1
135 338 4htxA Crystal structure of pde2 catalytic domain in complex with bay60-7550
133 328 4e90A Human phosphodiesterase 9 in complex with inhibitors
124 307 4dffA The sar development of dihydroimidazoisoquinoline derivatives as phosphodiesterase 10a inhibitors for the treatment of schizophrenia
128 318 4ddlA Pde10a crystal structure complexed with novel inhibitor
131 340 4d09A Pde2a catalytic domain in complex with a brain penetrant inhibitor
136 339 4d08A Pde2a catalytic domain in complex with a brain penetrant inhibitor
128 325 4c1iA Selective inhibitors of pde2, pde9, and pde10: modulators of activity of the central nervous system
124 312 4bbxA Discovery of a potent, selective and orally active pde10a inhibitor for the treatment of schizophrenia
131 320 4aelA Pde10a in complex with the inhibitor az5
140 328 4ajfA Identification and structural characterization of pde10 fragment inhibitors
131 321 4ajgA Identification and structural characterization of pde10 fragment inhibitors
133 324 4ajdA Identification and structural characterization of pde10 fragment inhibitors
135 320 4ajmA Development of a plate-based optical biosensor methodology to identify pde10 fragment inhibitors
136 358 3wd9A Crystal structure of phosphodiesterase 4b in complex with compound 10f
123 315 3wylA Crystal structure of the catalytic domain of pde10a complexed with 5-methoxy-3-(1-phenyl-1h-pyrazol-5-yl)-1-(3-(trifluoromethyl)phenyl)pyridazin-4(1h)-one
125 324 3wi2A Crystal structure of pde10a in complex with inhibitor
128 315 3wymA Crystal structure of the catalytic domain of pde10a complexed with 1-(2-fluoro-4-(1h-pyrazol-1-yl)phenyl)-5-methoxy-3-(1-phenyl-1h-pyrazol-5-yl)pyridazin-4(1h)-one
127 324 3ws8A Crystal structure of pde10a in complex with a benzimidazole inhibitor
125 315 3wykA Crystal structure of the catalytic domain of pde10a complexed with 3-(1-phenyl-1h-pyrazol-5-yl)-1-(3-(trifluoromethyl)phenyl)pyridazin-4(1h)-one
123 324 3ws9A Crystal structure of pde10a in complex with a benzimdazole inhibitor
131 358 3w5eA Crystal structure of phosphodiesterase 4b in complex with compound 31e
123 332 3v94A Tcrpdec1 catalytic domain in complex with inhibitor wyq16
127 332 3v93A Unliganded structure of tcrpdec1 catalytic domain
137 331 3v9bA Crystal structure of the catalytic domain of pde4d2 with (s)-n-(3-{1-[1-(3-cyclopropylmethoxy-4-difluoromethoxyphenyl)-2-(1-oxypyridin-4-yl)-ethyl]-1h-pyrazl-3-yl}phenyl)acetamide
126 305 3uuoA The discovery of potent, selectivity, and orally bioavailable pyrozoloquinolines as pde10 inhibitors for the treatment of schizophrenia
124 315 3ui7A Discovery of orally active pyrazoloquinoline as a potent pde10 inhibitor for the management of schizophrenia
135 334 3tvxA The structure of pde4a with pentoxifylline at 2.84a resolution
123 322 3sniA Highly potent, selective, and orally active phosphodiestarase 10a inhibitors
138 327 3sl3A Crystal structure of the apo form of the catalytic domain of pde4d2
136 327 3sl6A Crystal structure of the catalytic domain of pde4d2 with compound 12c
129 322 3snlA Highly potent, selective, and orally active phosphodiestarase 10a inhibitors
116 325 3shzA Crystal structure of the pde5a1 catalytic domain in complex with novel inhibitors
136 322 3sn7A Highly potent, selective, and orally active phosphodiestarase 10a inhibitors
139 327 3sl8A Crystal structure of the catalytic domain of pde4d2 with compound 10o